Who is affected by this change?

This affects Independence Blue Cross Dermatology, Rheumatology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Mar 5, 2025.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.098a, Tildrakizumab-asmn (Ilumya®)

Independence Blue Cross·Dermatology, Rheumatology·Pharmacy

Effective date

Mar 5, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.098a for Tildrakizumab-asmn (Ilumya®) has been reissued and updated. This affects coverage and billing for this specialty psoriasis medication under Medicare Advantage plans, though specific changes require reviewing the full policy document.

Action Required

Action needed

By March 5, 2025: Billing team must review the updated MA08.098a policy for Tildrakizumab-asmn (Ilumya®) at the provided URL to identify specific coverage, prior authorization, or billing changes. Update billing procedures accordingly for Medicare Advantage patients receiving this psoriasis treatment.

Related policy hubs

Independence Blue Cross policies Dermatology Rheumatology